Загрузка видео...

Не удалось загрузить видео

На главную

Pfizer CEO Albert Bourla has announced that the company will launch a new “once-a-month” shot designed to address America’s obesity problem. The announcement follows Pfizer’s acquisition of Metsera Inc., a biotech startup developing next-generation weight loss treatments. Bourla says people want this option and suggests the new monthly shot...

ShadowofEzra's profile picture

Shadow of Ezra

890,427 subscribers

302,599 просмотров • 8 месяцев назад •via X (Twitter)

Еда
LIVE

Anya Rossi• Live Now

Private livecam show

Комментарии: 0

Нет доступных комментариев

Здесь появятся комментарии из оригинального поста

Похожие видео

Two of the leading experts on anti-obesity drugs said new weight-loss medicines could soon be used to treat other conditions, including liver disease, kidney disease, arthritis and sleep apnea.
1:10

Two of the leading experts on anti-obesity drugs said new weight-loss medicines could soon be used to treat other conditions, including liver disease, kidney disease, arthritis and sleep apnea.

DealBook

19,942 просмотров • 1 год назад

Pfizer CEO Albert Bourla has a public meltdown at the World Economic Forum over growing numbers of people refusing vaccines, calling it a “new religion.” He says he’s deeply concerned and frustrated, blasting what he describes as religion-driven, anti-science rhetoric. Bourla claims the only solution is to immediately replace RFK Jr.
0:40

Pfizer CEO Albert Bourla has a public meltdown at the World Economic Forum over growing numbers of people refusing vaccines, calling it a “new religion.” He says he’s deeply concerned and frustrated, blasting what he describes as religion-driven, anti-science rhetoric. Bourla claims the only solution is to immediately replace RFK Jr.

Shadow of Ezra

538,899 просмотров • 5 месяцев назад

A brand new drug from $BHVN promises to promote muscle gain in patients taking GLP-1 obesity drugs CEO Vlad Coric breaks down the treatment's latest clinical trial results and how soon it could impact patients and the weight loss space:
5:25

A brand new drug from $BHVN promises to promote muscle gain in patients taking GLP-1 obesity drugs CEO Vlad Coric breaks down the treatment's latest clinical trial results and how soon it could impact patients and the weight loss space:

CNBC's Fast Money

39,012 просмотров • 2 лет назад

A Dutch court has ORDERED Bill Gates and Pfizer CEO Albert Bourla to testify over COVID shot crimes — accused of genocide and crimes against humanity. The court will examine whether mRNA shots functioned as a bioweapon. A high-stakes substantive hearing is set for October 22.
0:40

A Dutch court has ORDERED Bill Gates and Pfizer CEO Albert Bourla to testify over COVID shot crimes — accused of genocide and crimes against humanity. The court will examine whether mRNA shots functioned as a bioweapon. A high-stakes substantive hearing is set for October 22.

Nicolas Hulscher, MPH

44,658 просмотров • 3 месяцев назад

Pfizer CEO Albert Bourla reveals that President Trump made four specific requests to lower drug prices in America — and Pfizer’s deal today meets ALL of them. The dealmaker strikes again. Bourla admitted America was in an “unfair situation” while “other rich nations refused to pay their fair share for the medical innovation.” The big winner in this deal, he says, is “the American patient.” “Who else is a winner here?” Bourla asked. “It is American innovation and American economy,” he answered.
1:40

Pfizer CEO Albert Bourla reveals that President Trump made four specific requests to lower drug prices in America — and Pfizer’s deal today meets ALL of them. The dealmaker strikes again. Bourla admitted America was in an “unfair situation” while “other rich nations refused to pay their fair share for the medical innovation.” The big winner in this deal, he says, is “the American patient.” “Who else is a winner here?” Bourla asked. “It is American innovation and American economy,” he answered.

The Vigilant Fox 🦊

180,845 просмотров • 9 месяцев назад

Pfizer CEO Albert Bourla, May, 2025: "The incidence of [colorectal] cancer [has been] increasing the last several years *significantly,* particularly among younger people." What Bourla does not say is that mRNA jabs, including Pfizer's, cause colorectal cancer—see tweets 2 & 3. This clip is of Bourla touting Braftovi (encorafenib), a targeted cancer drug used to treat colorectal cancer. So Pfizer has helped to create the "significant" rise in colorectal cancers, particularly among younger people, and now it's going to profit off the harm with more "treatment."
0:48

Pfizer CEO Albert Bourla, May, 2025: "The incidence of [colorectal] cancer [has been] increasing the last several years *significantly,* particularly among younger people." What Bourla does not say is that mRNA jabs, including Pfizer's, cause colorectal cancer—see tweets 2 & 3. This clip is of Bourla touting Braftovi (encorafenib), a targeted cancer drug used to treat colorectal cancer. So Pfizer has helped to create the "significant" rise in colorectal cancers, particularly among younger people, and now it's going to profit off the harm with more "treatment."

Sense Receptor

115,265 просмотров • 1 год назад

Wes Streeting has suggested weight-loss jabs could be offered to millions more people on the NHS in a bid to tackle obesity. Should taxpayers foot the bill for wider access to the drugs? ateh jewel, HonDmedia and Dr Bhasha Mukherjee debate.
2:56

Wes Streeting has suggested weight-loss jabs could be offered to millions more people on the NHS in a bid to tackle obesity. Should taxpayers foot the bill for wider access to the drugs? ateh jewel, HonDmedia and Dr Bhasha Mukherjee debate.

Good Morning Britain

21,566 просмотров • 9 месяцев назад

Last week Tom Brady appeared in a multi-million dollar Pizza Hut ad blitz. This week, he announced that he’s now the new “Chief Wellness Officer” of a company that distributes weight loss drugs. The entire American economy is built on making people sick and selling a drug. 😒
1:31

Last week Tom Brady appeared in a multi-million dollar Pizza Hut ad blitz. This week, he announced that he’s now the new “Chief Wellness Officer” of a company that distributes weight loss drugs. The entire American economy is built on making people sick and selling a drug. 😒

James Li

141,577 просмотров • 6 месяцев назад

A new study has found that the active ingredient in popular weight loss drugs like Wegovy and Ozempic could reduce the risk of dying from COVID-19 in certain patients. Faith Abubéy has details.
1:38

A new study has found that the active ingredient in popular weight loss drugs like Wegovy and Ozempic could reduce the risk of dying from COVID-19 in certain patients. Faith Abubéy has details.

World News Tonight

118,983 просмотров • 1 год назад

'Is this a good use of the government's money?' Treasury Minister James Murray says 'it's really important that we tackle the obesity crisis' and the government's new plan to give weight loss jabs to overweight unemployed people is 'an important part' of it.
1:16

'Is this a good use of the government's money?' Treasury Minister James Murray says 'it's really important that we tackle the obesity crisis' and the government's new plan to give weight loss jabs to overweight unemployed people is 'an important part' of it.

Good Morning Britain

24,303 просмотров • 1 год назад

“We are watching a superpower developing super scientific capabilities, and our whole effort is how to slow [China] down, rather than how to become better than them,” says Albert Bourla, chairman and CEO of Pfizer, Inc. “The only way to be able not to lose the edge that we have—it is if we do changes inside our American ecosystem of biotech, of science, of academia, of pharmaceuticals, of capital markets, venture capital.” 🔗 Watch the full conversation:
0:40

“We are watching a superpower developing super scientific capabilities, and our whole effort is how to slow [China] down, rather than how to become better than them,” says Albert Bourla, chairman and CEO of Pfizer, Inc. “The only way to be able not to lose the edge that we have—it is if we do changes inside our American ecosystem of biotech, of science, of academia, of pharmaceuticals, of capital markets, venture capital.” 🔗 Watch the full conversation:

Council on Foreign Relations

59,948 просмотров • 3 месяцев назад

Amazon has announced that it will launch a new dedicated store in Ireland next year, The company says the new website will allow customers to browse products "with clearer, local pricing, and without additional customs charges."
0:53

Amazon has announced that it will launch a new dedicated store in Ireland next year, The company says the new website will allow customers to browse products "with clearer, local pricing, and without additional customs charges."

RTÉ News

406,046 просмотров • 2 лет назад

The popular Tapatio Hot Sauce brand has been purchased by a private equity firm The family had never write the recipe down, it was always mixed in private by only people who knew it by memory The recipe had to be written down and given to the private equity firm so they could expand distribution out of California The Saavedra family had run the company for over 50 years out of Los Angeles The new private equity firm owned say there is a stronger demand for hotter hot sauces throughout America because of drugs like Ozempic GLP-1 weight-loss drugs apparently is caused people to crave more spice and taste in their meals “As users of Ozempic and other weight loss drugs demand more flavor than they used to”
1:25

The popular Tapatio Hot Sauce brand has been purchased by a private equity firm The family had never write the recipe down, it was always mixed in private by only people who knew it by memory The recipe had to be written down and given to the private equity firm so they could expand distribution out of California The Saavedra family had run the company for over 50 years out of Los Angeles The new private equity firm owned say there is a stronger demand for hotter hot sauces throughout America because of drugs like Ozempic GLP-1 weight-loss drugs apparently is caused people to crave more spice and taste in their meals “As users of Ozempic and other weight loss drugs demand more flavor than they used to”

Wall Street Apes

641,967 просмотров • 2 месяцев назад

What makes Pfizer CEO Albert Bourla so certain there will be a tsunami of cancer between 2025-2030? Confident enough to pay 43 billion for a cancer company generating only 2 billion in revenue. Bold enough to assert that they are going to scale up cancer treatment technologies to levels the world has never seen before. Sure that this will be their next big revenue stream. How convenient that turbo cancer suddenly appeared.
3:40

What makes Pfizer CEO Albert Bourla so certain there will be a tsunami of cancer between 2025-2030? Confident enough to pay 43 billion for a cancer company generating only 2 billion in revenue. Bold enough to assert that they are going to scale up cancer treatment technologies to levels the world has never seen before. Sure that this will be their next big revenue stream. How convenient that turbo cancer suddenly appeared.

Kat A 🌸

476,958 просмотров • 2 лет назад

Andrew Huberman just broke down the next wave of weight-loss drugs on Gwyneth Paltrow’s goop podcast. He says the new triple agonist Retatrutide (currently in trials) is a big step up from Ozempic and Mounjaro. It hits three pathways (GLP-1 + glucagon + GIP) more gently, leading to significant weight loss with potentially less muscle loss and fewer side effects. People are already hunting for gray/black market versions. Early trial data on Retatrutide showed participants losing up to 24% of their body weight over 48 weeks, with notably better muscle preservation compared to earlier GLP-1 drugs when combined with resistance training. These next-generation drugs are becoming more targeted, but access, safety, and proper use remain key issues. This conversation made the rapid evolution of these drugs feel very real. It’s wild how fast this space is moving. What’s your take on the new generation of GLP drugs like Retatrutide?
3:32

Andrew Huberman just broke down the next wave of weight-loss drugs on Gwyneth Paltrow’s goop podcast. He says the new triple agonist Retatrutide (currently in trials) is a big step up from Ozempic and Mounjaro. It hits three pathways (GLP-1 + glucagon + GIP) more gently, leading to significant weight loss with potentially less muscle loss and fewer side effects. People are already hunting for gray/black market versions. Early trial data on Retatrutide showed participants losing up to 24% of their body weight over 48 weeks, with notably better muscle preservation compared to earlier GLP-1 drugs when combined with resistance training. These next-generation drugs are becoming more targeted, but access, safety, and proper use remain key issues. This conversation made the rapid evolution of these drugs feel very real. It’s wild how fast this space is moving. What’s your take on the new generation of GLP drugs like Retatrutide?

Camus

358,051 просмотров • 1 месяц назад

At Edison, we are on a mission to leverage AI to prevent or cure all diseases. Today, we are announcing a critical step: our first partnership using our AI scientist, Kosmos, to launch new biotech companies. Many of the most transformative new medicines begin life in biotech companies rather than big pharmas. We are partnering with Population Health Partners (PHP) to deploy Kosmos across their company creation pipeline. Kosmos will assist in the creation of PHP’s companies, allowing us to bring more medicines to patients. PHP has an outstanding track record of incubating successful biotech companies like Metsera Inc. (acquired by Pfizer Inc. in a $10B deal), and The Medicines Company (acquired by Novartis for $9.7B), to name just two. With PHP, we will focus on biotechs treating population-scale diseases like cardiovascular disease and obesity. If we can scale up the process of launching Metsera-style companies, we have an opportunity to transform medicine in the coming years.
1:57

At Edison, we are on a mission to leverage AI to prevent or cure all diseases. Today, we are announcing a critical step: our first partnership using our AI scientist, Kosmos, to launch new biotech companies. Many of the most transformative new medicines begin life in biotech companies rather than big pharmas. We are partnering with Population Health Partners (PHP) to deploy Kosmos across their company creation pipeline. Kosmos will assist in the creation of PHP’s companies, allowing us to bring more medicines to patients. PHP has an outstanding track record of incubating successful biotech companies like Metsera Inc. (acquired by Pfizer Inc. in a $10B deal), and The Medicines Company (acquired by Novartis for $9.7B), to name just two. With PHP, we will focus on biotechs treating population-scale diseases like cardiovascular disease and obesity. If we can scale up the process of launching Metsera-style companies, we have an opportunity to transform medicine in the coming years.

Sam Rodriques

30,604 просмотров • 15 дней назад

Dr. Boz: Ozempic should NOT be allowed for weight loss Dr. Boz (Annette Bosworth, MD) warns that the weight loss hype around Ozempic hides a serious problem. She explains that while patients show dramatic reductions in body weight, the underlying mechanism resembles controlled starvation—not metabolic healing. The result: rapid loss of not just fat, but muscle mass, bone density, and immune strength. According to Dr. Boz, older patients are especially vulnerable. Once muscle mass is lost at that rate, regaining it requires extreme measures—sometimes impossible past a certain age. She cautions that this kind of “weight loss” is actually a decline in body integrity that could shorten lifespan. “Put this in a time capsule,” she says. “Fifteen years from now, we’ll look back and realize Ozempic didn’t make people leaner; it made them weaker.”
0:44

Dr. Boz: Ozempic should NOT be allowed for weight loss Dr. Boz (Annette Bosworth, MD) warns that the weight loss hype around Ozempic hides a serious problem. She explains that while patients show dramatic reductions in body weight, the underlying mechanism resembles controlled starvation—not metabolic healing. The result: rapid loss of not just fat, but muscle mass, bone density, and immune strength. According to Dr. Boz, older patients are especially vulnerable. Once muscle mass is lost at that rate, regaining it requires extreme measures—sometimes impossible past a certain age. She cautions that this kind of “weight loss” is actually a decline in body integrity that could shorten lifespan. “Put this in a time capsule,” she says. “Fifteen years from now, we’ll look back and realize Ozempic didn’t make people leaner; it made them weaker.”

Camus

96,525 просмотров • 8 месяцев назад

#WATCH | Delhi: On GLP-1 Drugs, Dr Nikhil Tandon, Delhi AIIMS professor and HOD of Department of Endocrinology and Metabolism, says, “We can take many steps to reduce obesity. The first and foremost step towards it is physical activities and diet… The medicines which are used in weight control are always given with a foundation of diet control and physical activity. We have to make changes in our lifestyle first to achieve weight loss… After all this, if we are still not achieving the required weight, we should consult a doctor… Earlier, there were some medicines for weight loss which were withdrawn due to their side effects… A medicine is only approved when the benefits outweigh the risks, and it can reduce up to 5% of your weight. The GLP-1 was initially used for diabetic management but was later found to have an impact on weight… But one should not consume it recklessly as these are serious medicines for a serious problem… People should be careful as there can be side-effects…”
3:08

#WATCH | Delhi: On GLP-1 Drugs, Dr Nikhil Tandon, Delhi AIIMS professor and HOD of Department of Endocrinology and Metabolism, says, “We can take many steps to reduce obesity. The first and foremost step towards it is physical activities and diet… The medicines which are used in weight control are always given with a foundation of diet control and physical activity. We have to make changes in our lifestyle first to achieve weight loss… After all this, if we are still not achieving the required weight, we should consult a doctor… Earlier, there were some medicines for weight loss which were withdrawn due to their side effects… A medicine is only approved when the benefits outweigh the risks, and it can reduce up to 5% of your weight. The GLP-1 was initially used for diabetic management but was later found to have an impact on weight… But one should not consume it recklessly as these are serious medicines for a serious problem… People should be careful as there can be side-effects…”

ANI

23,109 просмотров • 3 месяцев назад

OOPS-EMPIC? WEIGHT-LOSS DRUG LINKED TO SURPRISE BABY BOOM New research suggests Ozempic and similar weight-loss drugs might do more than shrink waistlines - they could be bumping up unexpected pregnancies. Turns out, while you're skipping dessert, Ozempic might be skipping your birth control too, with doctors warning it may interfere with hormonal contraception. Add possible immune suppression and metabolic side effects, and suddenly the miracle drug looks more like a plot twist. Fertility crash meets skinny-shot surprise baby boom - because apparently nothing is simple anymore. Source: Independent
1:04

OOPS-EMPIC? WEIGHT-LOSS DRUG LINKED TO SURPRISE BABY BOOM New research suggests Ozempic and similar weight-loss drugs might do more than shrink waistlines - they could be bumping up unexpected pregnancies. Turns out, while you're skipping dessert, Ozempic might be skipping your birth control too, with doctors warning it may interfere with hormonal contraception. Add possible immune suppression and metabolic side effects, and suddenly the miracle drug looks more like a plot twist. Fertility crash meets skinny-shot surprise baby boom - because apparently nothing is simple anymore. Source: Independent

Mario Nawfal

469,085 просмотров • 1 год назад